Pharmaceutical Executive February 12, 2024
The FDA granted accelerated approval to Elahere in November 2022 for adults with folate receptor-alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
AbbVie has completed its acquisition of ImmunoGen in a deal that was announced in November 2023, which bolsters the company’s pipeline of antibody drug conjugates (ADCs).1 As part of the transaction, AbbVie acquired in cash all outstanding shares of ImmunoGen for $31.26 per share, valuing ImmunoGen at a total equity value of approximately $10.1 billion.
“Together with ImmunoGen, we have the potential to continue redefining the standard of care for those living with cancer,” AbbVie President and Chief Operating Officer Robert A. Michael, said in a press release. “The addition of ImmunoGen’s treatment...
Today's Sponsors
Today's Sponsor